NCT01081873

Study to Document Treatment Patterns and to Evaluate Leuprolide and Alternative Therapeutic Approaches to the Treatments of Advanced Prostate Cancer

A Post-Marketing Observational Study to Document Treatment Patterns and to Evaluate Leuprolide and Alternative Therapeutic Approaches to the Treatment of Advanced Prostate Cancer

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 2,717 (actual)
• Sponsor: Abbott · Industry
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Document treatment patterns and evaluate LUCRIN / LUCRIN-TRIDEPOT® (Leuprolide) and alternative therapeutic approaches to the treatment of advanced prostate cancer during normal clinical practice and in accordance with the terms of the Belgian marketing authorization and reimbursement conditions.

Conditions

• Prostatic Neoplasm

Interventions

Type	Name	Description
DRUG	leuprolide (Lucrin/Lucrin-Tri-depot)	Subcutaneous or intramuscular administration for all participants

Timeline

• Start date: 2004-06-01
• Primary completion: 2010-12-01
• Completion: 2010-12-01
• First posted: 2010-03-05
• Last updated: 2012-10-31
• Results posted: 2012-03-26

Locations

135 sites across 2 countries: Belgium, Luxembourg